KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Finished Goods (2016 - 2017)

Amgen has reported Finished Goods over the past 5 years, most recently at $1.1 billion for Q2 2017.

  • For Q2 2017, Finished Goods changed N/A year-over-year to $1.1 billion; the TTM value through Jun 2017 reached $1.1 billion, changed N/A, while the annual FY2016 figure was $912.0 million, 29.36% up from the prior year.
  • Finished Goods for Q2 2017 was $1.1 billion at Amgen, down from $1.2 billion in the prior quarter.
  • Over five years, Finished Goods peaked at $1.2 billion in Q1 2017 and troughed at $705.0 million in Q4 2015.
  • A 5-year average of $920.5 million and a median of $914.0 million in 2014 define the central range for Finished Goods.
  • Biggest five-year swings in Finished Goods: fell 21.49% in 2015 and later skyrocketed 48.02% in 2017.
  • Year by year, Finished Goods stood at $738.0 million in 2013, then grew by 21.68% to $898.0 million in 2014, then fell by 21.49% to $705.0 million in 2015, then grew by 29.36% to $912.0 million in 2016, then increased by 21.27% to $1.1 billion in 2017.
  • Business Quant data shows Finished Goods for AMGN at $1.1 billion in Q2 2017, $1.2 billion in Q1 2017, and $912.0 million in Q4 2016.